Fung-AI prioritizes peptides with measured antifungal activity
Fung-AI combines a generative adversarial network with learned antifungal and hemolysis classifiers to select peptides for testing. The study first tested five peptides from separate clusters; activity of peptide 40 prompted testing of eight more members from cluster 17. Five of the nine tested cluster-17 peptides inhibited Fusarium graminearum, a post-selection cluster-specific outcome—not a general 5/13 model hit rate. Four peptides showed activity against Candida albicans, while none inhibited C. auris up to 500 μg/mL. The paper’s HepG2 cytotoxicity statements are internally inconsistent for peptide 48 and peptide 65, and peptide 12 and 40 have reported cytotoxicity; these assays establish neither human safety nor clinical efficacy.
Technology: Fung-AI GAN; learned antifungal and hemolysis classifiers
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article reports staged testing, fungal MICs and cell-line cytotoxicity; adaptive denominator and conflicting LC50 statements were reconciled in the continuation audit.
- Still unknown: Sequence-level prior art and independent replication not assessed; HepG2 assays do not establish human safety.
- AI role: GAN generates candidates; antifungal and hemolysis classifiers narrow the candidate set before synthesis and fungal assays.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13289945/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary PLOS article and indexed PMC full text checked; follow-up audit read full article and resolves staged denominator and LC50 inconsistency, not by remeasurement..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.